Hepatocyte Production via Forward Programming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an efficient method to produce an unlimited supply of patient-specific hepatocytes for drug development and transplantation therapies, as human primary hepatocytes quickly lose function in culture and exhibit individual variability in drug metabolism.
Innovation Solution
The method involves forward programming of somatic cells or stem cells into hepatocytes by increasing the expression of hepatocyte programming factor genes, such as FOXA1, FOXA2, HNF1A, and HNF4A, to directly differentiate them into hepatocytes without the need for intermediate stages or additional growth factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human primary hepatocytes are cultured in vitro, then they can be used for drug toxicity screening and development, but they quickly lose their functions and exhibit significant individual variability
Solution Approach 1:
The patent applies preliminary action by pre-programming somatic cells with hepatocyte-specific transcription factors (HNF4A, HNF1A, FOXA1, FOXA2) before culture. This genetic programming is performed in advance to establish hepatocyte identity and function, ensuring that cells maintain their functional characteristics throughout the culture period without degradation over time.
Solution Approach 2:
The patent creates genetically engineered cell lines that copy and maintain hepatocyte-specific gene expression patterns. By introducing and stably expressing hepatocyte programming factor genes, the cells replicate the molecular profile of primary hepatocytes, providing a renewable source with consistent drug metabolism functions that can be used indefinitely for screening purposes.
2Productivity
If step-wise differentiation through intermediate stages is used, then cells can be differentiated into hepatocytes, but it requires adding different growth factors at different time points which increases labor, time and expenses
Solution Approach 1:
The patent extracts and eliminates the need for intermediate differentiation stages by directly programming somatic cells with hepatocyte-specific transcription factors. This approach removes the complex multi-step process involving sequential addition of growth factors (such as FGFs, EGFs, and nicotinamides) at different time points, simplifying the protocol to a single direct programming step that achieves the same endpoint more efficiently.
Solution Approach 2:
The patent inverts the conventional differentiation approach by instead of progressing from undifferentiated to differentiated states through intermediate stages, it directly imposes hepatocyte identity on somatic cells through genetic programming. This reverse logic bypasses the natural developmental sequence, achieving hepatocyte differentiation in a single step rather than through multiple sequential stages.
Data Source
AI summary
The invention generally features methods for providing hepatocytes from a variety of cell sources, particularly pluripotent stem cells, therapeutic compositions featuring such cells, and methods of using them for the treatment of subjects.